Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer

Keila S. Espinoza, Ashley J. Snider

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Inflammatory bowel disease (IBD), characterized by chronic inflammation in the intestinal tract, increases the risk for the development of colorectal cancer (CRC). Sphingolipids, which have been implicated in IBD and CRC, are a class of bioactive lipids that regulate cell signaling, differentiation, apoptosis, inflammation, and survival. The balance between ceramide (Cer), the central sphingolipid involved in apoptosis and differentiation, and sphingosine-1-phosphate (S1P), a potent signaling molecule involved in proliferation and inflammation, is vital for the maintenance of normal cellular function. Altered sphingolipid metabolism has been implicated in IBD and CRC, with many studies highlighting the importance of S1P in inflammatory signaling and pro-survival pathways. A myriad of sphingolipid analogues, inhibitors, and modulators have been developed to target the sphingolipid metabolic pathway. In this review, the efficacy and therapeutic potential for modulation of sphingolipid metabolism in IBD and CRC will be discussed.

Original languageEnglish (US)
Article number789
Issue number4
StatePublished - Feb 2024


  • ceramide
  • colitis-associated cancer
  • colorectal cancer
  • inflammation
  • inflammatory bowel disease
  • sphingolipids
  • sphingosine-1-phosphate

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer'. Together they form a unique fingerprint.

Cite this